



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

FIKES *et al.*

Appl. No.: 10/553,703

I.A. Filed: April 16, 2004

For: **HLA-A2 Tumor Associated
Antigen Peptides and Compositions**

Confirmation No.: 4669

Art Unit: *To be assigned*

Examiner: *To be assigned*

Atty. Docket: 2060.0150007/EKS/PAC

**Amendment and Submission of Substitute Sequence Listing
Under 37 C.F.R. § 1.825(a)**

Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

Sir:

In compliance with 37 C.F.R. § 1.825(a), Applicants submit substitute sheets to amend the paper copy of the Sequence Listing.

Amendments to the Sequence Listing begin on page 2 of this paper and include an attached sequence listing.

Remarks begin on page 3 of this paper.

It is not believed that extensions of time or fees for net addition of claims are required beyond those that may otherwise be provided for in documents accompanying this paper. However, if additional extensions of time are necessary to prevent abandonment of this application, then such extensions of time are hereby petitioned under 37 C.F.R. § 1.136(a), and any fees required therefor (including fees for net addition of claims) are hereby authorized to be charged to our Deposit Account No. 19 0036.